JECCR Impact Factor

The first useful signal is that JECCR has become a strong citation owner for translational oncology work. This is not just a good number for an open-access cancer journal. It is a strong number for any cancer journal operating below the highest general-oncology flagships.

The second useful signal is the cleanliness of the profile. The JIF without self-cites is 12.7, almost identical to the headline JIF. That suggests the current number is not being propped up by internal citation concentration.

The third useful signal is the JCI of 2.45. That matters because oncology citation cultures can vary sharply between mechanistic biology, biomarker studies, immunotherapy, and large-scale profiling work. A JCI above 2 says the journal is performing well even after field normalization.

The JCR row above is the authoritative impact factor on this page. The Scopus-based series below is a directional check on JECCR's bench-to-bedside oncology citation demand, not a replacement for the JCR row.

Directionally, the open citation signal is up from 9.65 in 2023 to 11.28 in 2024. The larger pattern is also clear: the journal is operating far above its mid-2010s baseline.

That usually means the market has become more confident about the journal's role. JECCR is no longer a marginal option for translational oncology. It is a serious destination when the paper has a believable bench-to-bedside bridge.

The common mistake is to read 14.3 and conclude that strong cancer biology alone should be enough.

That is not how the journal describes itself publicly. Its official aims explicitly ask for significant advances in basic cancer research that offer a translational bridge from the laboratory to the clinic.

In practice, the journal tends to reward papers where:

• the translational consequence is tied to the evidence

• biomarkers, targets, or tumor-characterization work change decision logic

• the patient-facing implication is more than hopeful framing

• the manuscript feels broad enough for a translational oncology audience

That means the metric tells you the journal has reach. It does not tell you that purely mechanistic cancer biology belongs there.

For manuscripts targeting JECCR, the repeat problem is not lack of novelty. It is a weak bridge.

We see strong cancer papers that are biologically interesting but still make the translational consequence do too much rhetorical work. Editors actually look for the bridge early, and the journal's public scope language is explicit about that.

For manuscripts targeting JECCR, four failure patterns recur.

The biology is strong but the bridge is thin. The paper says therapy, diagnosis, or patient relevance, but the figures still behave mostly like mechanistic cancer biology.

The biomarker story is not actionable enough. Omics and biomarker papers can attract attention, but editors usually want a clearer reason the work changes oncology thinking or strategy.

The clinical claim outruns the dataset. This is common in papers that imply treatment or resistance consequence before the evidence fully supports it.

The first read buries the consequence. A good translational paper can still look ordinary if the title, abstract, and first figures delay the bench-to-bedside logic.

If that sounds like the paper, a JECCR submission readiness check is usually more useful than another round of cosmetic revision.

The impact factor does not tell you whether the biomarker story is actionable enough, whether the clinical bridge is real enough, or whether the strongest claim is still too inferential for the journal's level.

That is where most JECCR mismatches happen. The metric places the journal. It does not make the bridge stronger.